What is the outlook for full‑year 2024/25 earnings and guidance – any revisions to revenue, EBITDA, or EPS forecasts?
Answer
The short news release you quoted does not contain any specific figures or commentary about Coloplast A/S’s full‑year 2024/25 earnings outlook, nor does it mention any revisions to the company’s revenue, EBITDA, or earnings‑per‑share (EPS) forecasts.
What the release does tell us is that Coloplast will:
- Publish its interim financial results for the first 9 months of the 2024/25 fiscal year (the “9M 2024/25” results) in the early‑morning of Tuesday 19 August 2025 (around 07:30 CEST).
- Host a conference call at 11:00 CEST (lasting roughly one hour) to present those results and answer questions from investors and analysts.
- Make a presentation available on its website about an hour before the call (i.e., around 10:00 CEST).
- Provide a webcast of the call both during the event and afterward.
Because the release is purely an invitation to the upcoming call and does not include the actual interim results or any forward‑looking guidance, we cannot give a concrete answer about:
- Revenue outlook for the full fiscal year 2024/25
- EBITDA expectations (including any upward or downward revisions)
- EPS guidance (including any changes to the prior forecast)
What to do next
- Attend (or view the recording of) the conference call on 19 August 2025. The management team will typically present the 9‑month results, compare them with the prior guidance, and then provide the updated full‑year outlook—including any revisions to revenue, EBITDA, and EPS.
- Download the presentation that will be posted on Coloplast’s website shortly before the call. Companies often embed the revised guidance in the slide deck, especially in the “Outlook” or “Guidance” sections.
- Check Coloplast’s press release and the accompanying “interim financial results” PDF that will be released around 07:30 CEST on the same day. Those documents normally contain a “Management’s Outlook” paragraph that spells out any changes to the 2024/25 forecasts.
- Monitor the “Investors” section of Coloplast’s website after the call for any supplemental material (e.g., an updated earnings guidance press release, a Q&A transcript, or a supplemental slide with revised forecasts).
Typical content you can expect in the guidance update
While we can’t confirm Coloplast’s specific numbers, earnings‑release calls for a 9‑month interim period usually address the following points, which will help you interpret any forthcoming revisions:
| Topic | What is usually disclosed | Why it matters |
|---|---|---|
| Revenue | Comparison of actual 9M revenue vs. prior guidance; statement on expected full‑year revenue growth rate (e.g., “we now expect FY 2024/25 revenue to grow 3‑4% vs. 5% previously”). | Impacts top‑line growth expectations and market share trends. |
| EBITDA | Current EBITDA margin for the 9M period; any changes to the FY EBITDA margin outlook (e.g., “EBITDA margin is now projected at 15.5% vs. 16% earlier”). | Drives cash‑flow expectations and valuation multiples. |
| EPS (net profit) | Interim net profit vs. forecast; any revision to the FY EPS target (e.g., “EPS guidance is raised to DKK X.XX per share”). | Directly influences shareholder return expectations and target‑price models. |
| Key drivers | Explanation of the underlying reasons for any upward or downward revisions (e.g., product‑mix shifts, pricing actions, cost‑efficiency programs, macro‑economic factors, regulatory updates). | Helps assess sustainability of the revised outlook. |
| Outlook for the remaining 3 months | Management will often give a “run‑off” forecast for Q4 2024/25, indicating whether the remaining quarter is expected to be “in line,” “above,” or “below” the prior plan. | Provides a more granular view of the FY trajectory. |
Bottom line
Based solely on the invitation you provided, we do not have the actual earnings outlook or any guidance revisions for full‑year 2024/25. The definitive answers will be disclosed in the interim results release and the conference‑call presentation that Coloplast makes available on 19 August 2025. To obtain the precise figures and any adjustments to revenue, EBITDA, or EPS forecasts, you’ll need to review those materials (or the subsequent press release that typically follows the call).